The PAPYRUS Study: Permanent vs. Absorbable Sutures in PrimarY Repair of Umbilical HerniaS: A Multicentre, Single-blind, Non-inferiority, Randomized Controlled Trial

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of British Columbia

About this trial

Umbilical hernias can be found in over a quarter of the population and comprise of 15% of hernia repairs performed in Canada. While mesh repair is commonly used for larger hernias, smaller hernia defects are often closed with sutures alone. While non-absorbable sutures may have greater tensile strength, the use of absorbable sutures has been found to reduce the risk for wound infection and improve healing. The objective of this multi-centre, nationwide randomized controlled study is to determine whether there is a difference in hernia recurrence when the repair is completed with absorbable polydioxanone suture versus permanent polypropylene suture. The study will also explore post-operative complications and quality of life. Recruitment will take place over 5 years with follow-up at the 30-day, 12-month and 24-month mark following surgery. The results of this trial will be directly applicable to national and international hernia guidelines and will impact the care of thousands of patients.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Elective surgery for primary umbilical hernia with a defect ≤ 2 cm measured clinically or radiographically

Age 19 years or older

Patient able to give oral and written informed consent

Disqualifiers

Umbilical hernia defect > 2 cm measured clinically, radiologically, or intraoperatively with ruler

Multiple defects

Incisional hernia: prior hernia in area of operation

Recurrent umbilical hernia

Trial design

Design model

Parallel

Treatments tested in this trial

  • Permanent Suture

    Other intervention

    In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed in a standardized manner. In the control group, a permanent 0-0 polypropylene suture will be used to close the hernia defect in a transverse or vertical interrupted fashion using either the simple interrupted or the figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.

  • Absorbable

    Other intervention

    In both control and intervention groups, an open umbilical hernia repair will be performed based on a standardized surgical technique. Dissection and identification of the fascial defect will be performed. An 0-0 polydioxanone suture (PDS) will be used to close the hernia defect in either a transverse or vertical interrupted fashion using either simple interrupted or figure-of-eight technique. If the surgeon creates an opening in the umbilical skin or extends the skin incision beyond the paraumbilical incision during the procedure, the participant will be excluded from the study.

Treatment groups

914 Participants
are divided into 2 treatment groups
Group A: Permenant SutureActive comparator 1 intervention
Group B: Absorbable SutureActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Recurrence

Recurrence will be diagnosed clinically at the time of follow-up. Clinical diagnosis of hernia recurrence will be determined by a standard medical assessment (ie. physical exam). In the event that clinical recurrence is uncertain, a computed tomography scan or ultrasound will be performed while the patient performs a Valsalva maneuver.

Time frame
24 months

Secondary outcomes

1

SSO

SSO will be diagnosed according to the Ventral Hernia Working Group definition which includes: surgical site infection, seroma, dehiscence, enterocutaneous fistula, surgical site infection, seroma, wound dehiscence, enterocutaneous fistula, wound cellulitis, non-healing incisional wound, fascial disruption, skin or soft tissue ischemia, skin or soft tissue necrosis, wound serous or purulent drainage, stitch abscess, seroma, hematoma, and infected or exposed mesh.

Time frame
30 days, 12 months, 24 months
2

SSOPI

Surgical Site Occurrences (SSOs) requiring a procedural intervention, defined as wound opening or debridement, suture excision, or percutaneous drainage

Time frame
30 days, 12 months, 24 months
3

Quality of Life - HerQLes

The Hernia-Related Quality of Life Survey (HerQLes) is a validated patient-reported outcome measure specific to abdominal wall hernias, verified in a subgroup analysis of patients with small hernias. The HerQLes includes 12 statements related to the abdominal wall. Each of the 12 statements is scored from 1 to 6 (strongly disagree to strongly agree, respectively). Each statement covers a domain relevant to hernia-related QoL, and the scores can be compared for each statement and in aggregate. Summary scores are calculated using the following formula: (120-\[(20/12)∗(raw score)\]).

Time frame
30 days, 12 months, 24 months
4

Quality of Life - SF-12

The 12-item Short Form Survey from the RAND Medical Outcomes Study (SF-12) is a general health status questionnaire, a truncated and validated version of the extensively used 36-item Short Form Survey (SF-36), used to assess baseline health and postoperative recovery. The SF-12 is a self-reported health-related QoL questionnaire comprised of 12 items, including 8 domains of health (physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health). In accordance with prior hernia research, the results of test items will be normalized and expressed in terms of 2 meta-scores: Physical Component Summary and Mental Component Summary. A higher SF-12 score is indicative of better functioning.

Time frame
30 days, 12 months, 24 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of British Columbia

Lead sponsor

North York General Hospital

Collaborator

Royal Victoria Hospital Of Barrie

Collaborator

London Health Sciences Centre

Collaborator

University of Alberta

Collaborator

This trial is not recruiting at the moment. You can still explore other options: